Sail Biomedicines Announces Strategic Collaboration to Develop New Class of Medicines for In Vivo CAR-T
Combines Sail’s patented eRNA™ and targeted nanoparticle modality with Johnson & Johnson’s world-class development, manufacturing, and commercialization capabilities to create scalable and potentially curative In Vivo CAR-T therapies for immune-mediated diseases
Sail to receive initial payments of $785 million from Johnson & Johnson1, including a $465 million equity investment2 and additional milestone payments of $140 million subject to achievement of certain development milestones
Johnson & Johnson3 to obtain an exclusive option to acquire Sail for an additional $2.58 billion
Sail Biomedicines, a Flagship Pioneering company creating a new class of RNA medicines, today announced a strategic collaboration with Johnson & Johnson to advance innovative In Vivo Chimeric Antigen Receptor T-cell (CAR-T) therapies that have the potential to improve patient outcomes for immune-mediated diseases. The collaboration will combine Sail’s pioneering AI-driven product design using its proprietary eRNA™ and targeted nanoparticle platform with Johnson & Johnson’s world-class capabilities in drug development, manufacturing, and commercialization. The companies will advance Sail’s vanguard In Vivo CAR-T program in autoimmune diseases while pursuing additional programs that leverage Sail’s industry leading product engine to build a portfolio of In Vivo CAR-T medicines designed to drive durable disease remission by resetting the immune system.
